scholarly journals Long-wavelength ultraviolet A (UVA-1) phototherapy for the treatment of patients with atopic dermatitis

2021 ◽  
Vol 97 (5) ◽  
pp. 26-37
Author(s):  
A. E. Karamova ◽  
V. V. Chikin ◽  
A. A. Kubanov ◽  
L. K. Davletbaeva
Keyword(s):  
Atopic Dermatitis ◽  
Drug Therapy ◽  
Side Effects ◽  
Radiation Dose ◽  
Mechanisms Of Action ◽  
Severe Atopic Dermatitis ◽  
Ultraviolet A ◽  
Long Wavelength ◽  
Discontinuation Of Treatment ◽  
Skin Phototype

One of the methods of therapy for atopic dermatitis is long-wavelength ultraviolet therapy A (UVA-1- therapy). This review aims to provide the mechanisms of action of UVA-1-therapy an overview about the effectiveness of UVA-1-therapy in patients with atopic dermatitis taking into account factors that can affect the effectiveness of treatment radiation dose, skin phototype of patients, concomitant drug therapy. The available data on a decrease in the severity of atopic dermatitis as a result of the course of UVA-1-therapy and on a decrease in the severity of itching in patients are presented. The data on the rate of onset of the therapeutic effect of UVA-1-therapy and the duration of its maintenance are considered. The safety of UVA-1-therapy is discussed, and the most frequent undesirable effects a feeling of warmth, fever, itching, hyperpigmentation, are given. The possibility of developing side effects requiring discontinuation of treatment is assessed. The data obtained indicate the effectiveness and safety of the UFA-1-radiation in the treatment of patients with moderate-to-severe atopic dermatitis.

scholarly journals Clinical and Therapeutic Trial for the Efficacy of Narrow Band - UVB Phototherapy versus Systemic Therapy in Moderate and Severe Atopic Dermatitis of the Adult

2018 ◽  
Vol 64 (1) ◽  
pp. 17-21
Author(s):  
Gyula Laszlo Fekete ◽  
László Fekete
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Systemic Therapy ◽  
Systemic Corticosteroid ◽  
Corticosteroid Treatment ◽  
Serum Levels ◽  
Severe Atopic Dermatitis ◽  
Therapeutic Trial ◽  
Group I ◽  
Uvb Phototherapy

AbstractObjectives: The aim of this clinical and therapy study was to evaluate the efficacy of NB-UVB phototherapy versus systemic therapy in moderate-to-severe atopic dermatitis of the adult.Material and methods: The subjects of the study were divided into two groups of 25 adult patients with moderate and severe atopic dermatitis according to the inclusion criteria. The first group of 25 patients were treated with systemic corticosteroids while the second group of 25 patients were treated with NB-UVB phototherapy. At the end of the study, after all the data were centralized, we performed a statistical analysis of the results, comparing the two groups as well as the efficacy of the different therapies.Results: In group I the clinical efficacy of the systemic corticosteroid treatment was achieved, on average, at 4 weeks in patients with moderate atopic dermatitis and at 6 weeks in patients with severe atopic dermatitis. In group II the clinical effecacy of NB-UVB phototherapy was achieved, on average, at 6 weeks for patients with moderate atopic dermatitis and at 8 weeks for those with the severe form. In both groups, the total IgE serum levels were elevated at the beginning, and they became normal throughout the clinical improvement. Remarkable therapy-related side effects were found in the first study group.Conclusion: We conclude that NB-UVB phototherapy had similar efficacy in treating moderate-to-severe atopic dermatitis with minimal side effects compared to systemic corticosteroid therapy.

Marfan syndrome in combination with severe atopic dermatitis: importance of early diagnosis and treatment of patients with allergic dermatitis in childhood

2021 ◽  
Vol 16 (2) ◽  
pp. 68-73
Author(s):  
P.G. Svist ◽  
◽  
E.V. Orlova ◽  
L.M. Smirnova ◽  
S.S. Parshintseva ◽  
...  
Keyword(s):  
Early Childhood ◽  
Atopic Dermatitis ◽  
Side Effects ◽  
Marfan Syndrome ◽  
Clinical Manifestations ◽  
Treatment Strategies ◽  
Hereditary Diseases ◽  
Severe Atopic Dermatitis ◽  
Key Words Atopic Dermatitis ◽  
Effective Treatment Regimen

We report a case of a rare combination of Marfan syndrome and severe atopic dermatitis (AD) in a 32-year-old male patient. He developed AD in early childhood and then had a relapse at the age of 18 years caused by stress. After this, AD became severe due to stress associated with aortic aneurysmectomy. The patient also had side effects caused by steroids, including multiple pustular eruptions, Kaposi's varicelliform eruption, edema and hyperemia of the periorbital area, pain and swelling of the small joints of the hands. These side effects, as well as specific cardiovascular symptoms typical of Marfan syndrome necessitated the search for alternative treatment strategies for severe AD. Eventually, we managed to find an effective treatment regimen that caused no side effects or adverse events, while the symptoms subsided. This case demonstrates the importance of early AD diagnosis in childhood in order to prevent its transition into severe chronic form that can hardly be managed in adulthood. Key words: atopic dermatitis, children, diagnostic criteria, clinical manifestations, hereditary diseases, Marfan syndrome

Hydrocortisone 17-Butyrate (Locoid®) 0.1% Fatty Cream versus Desonide (Apolar®) 0·1% Ointment in the Treatment of Patients Suffering from Atopic Dermatitis

1986 ◽  
Vol 14 (2) ◽  
pp. 85-90 ◽  
Author(s):  
G Rajka ◽  
H L Veijans
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Skin Diseases ◽  
Skin Lesions ◽  
Severe Atopic Dermatitis ◽  
Double Blind ◽  
Application Form ◽  
Wide Range ◽  
Ointment Formulation ◽  
Efficacy Of Treatment

A randomized, double-blind, left-right study to compare the therapeutic efficacy and the cosmetic acceptability of the new hydrocortisone 17-butyrate (Locoid®) 0·1% fatty cream application form with desonide (Apolar®) 0·1% ointment was performed in thirty patients suffering from moderate to severe atopic dermatitis. The medications were applied to symmetrical, bilateral skin lesions twice daily for 4 weeks. Both treatments effected highly significant reductions of the score values for the severity of all clinical skin parameters assessed. Score reductions were, however, more pronounced on Locoid-treated sides than on Apolar-treated sides both after 2 and 4 weeks of therapy. It appeared further that clinical efficacy of treatment at completion of the study was also in favour of Locoid-treated sides, indicating that Locoid fatty cream is more effective than Apolar ointment. No serious side-effects were reported during the study. The expressed patient preferences with respect to cosmetic acceptability of treatments were significantly in favour of Locoid fatty cream, indicating that patients preferred the use of this new galenic formulation over an ointment formulation. It is concluded that the new application form of Locoid, a fatty cream, is a useful and beneficial addition to topical corticosteroid therapy, which will promote patient compliance in a wide range of corticosteroid-responsive skin diseases.

scholarly journals A Retrospective Analysis of Real Life Medication Regimens for Adults with Atopic Dermatitis on Immunosuppressive Medication (Ramadil) In a Single Third Line Center in Belgium

2017 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Systemic Treatment ◽  
Real Life ◽  
Immunosuppressive Drugs ◽  
Line Center ◽  
Severe Atopic Dermatitis ◽  
Therapeutic Effects ◽  
Immunosuppressive Medication ◽  
Third Line

Few Belgian data are available on the treatment of severe atopic dermatitis in adults. As in most other countries, only cyclosporine A is registered for the systemic treatment of atopic dermatitis. Although treatment periods are restricted, side effects may occur, and response failure is possible. Small trials with other immunosuppressive drugs (azathioprine, mofetylmycophenolate, and methotrexate) have indicated they may improve atopic dermatitis, although their effect is slower than with cyclosporine. In the future, treatment of atopic dermatitis may drastically change as the therapeutic effects of new biologicals are promising. This RAMADIL study, from a third line referral center in Belgium, was conducted in order to collect information about the way AD is treated in this pre-biological era.

scholarly journals Long-Term Efficacy and Safety of Intravenous Injection of Clonal Mesenchymal Stem Cells Derived From Bone Marrow in Five Adults With Moderate to Severe Atopic Dermatitis

2020 ◽  
Author(s):  
Hyun-Tae Shin ◽  
Si Hyub Lee ◽  
Hee Seong Yoon ◽  
Ji Hye Heo ◽  
Seon Bok Lee ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Clinical Response ◽  
Response Assessment ◽  
Severity Index ◽  
Severe Atopic Dermatitis ◽  
Efficacy And Safety ◽  
Mesenchymal Stem Cell Therapy ◽  
Term Efficacy

Abstract Atopic dermatitis is a chronic and relapsing inflammatory skin disease that is treated with immunosuppressants. However, long-term use of immunosuppressants may cause toxicity and severe side effects. To confirm the long-term efficacy and safety of clonal mesenchymal stem cell therapy, we performed investigator-initiated clinical trials and long-term observation in five adult patients with moderate to severe atopic dermatitis that was refractory to conventional treatments. The clinical response assessment values such as eczema area and severity index (EASI) improved significantly at 16 weeks, and 80% (4/5) of the patients achieved EASI-50 after one or two treatment cycles. Patients were observed for long-term efficacy and safety for an average of 38 weeks (range: 16–86 weeks) and showed no serious side effects. Among the cytokines tested, CCL-17, IL-13 and IL-22 significantly decreased at the endpoint of the five participants, two patients who maintained good clinical response over 84 weeks showed increased IL-17 cytokine levels in the blood.

COMBINATION OF POTASSIUM PERCHLORATE AND PROPYLTHIOURACIL IN THE TREATMENT OF THYROTOXICOSIS

1968 ◽  
Vol 57 (4) ◽  
pp. 565-577 ◽  
Author(s):  
K. E. Røkke ◽  
J. H. Vogt
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Metabolic Rate ◽  
Total Cholesterol ◽  
Basal Metabolic Rate ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Control Measures ◽  
Potassium Perchlorate ◽  
Plasma Total Cholesterol

ABSTRACT A report is given on 95 thyrotoxic patients treated with a combination of 400 mg propylthiouracil and 400 mg of potassium perchlorate. Perchlorate was stopped when a marked remission of symptoms was obtained, on an average after less than 7 weeks. Euthyroidism was found on an average after 7.2 weeks. The basal metabolic rate, PBI, plasma total cholesterol and weight showed a fairly rapid normalization. Thirteen of the 95 patients were given radio-iodine therapy shortly before drug therapy was started. The remaining 82 cases were grouped together with the 23 cases previously reported. Of the total of 105 cases, 96 became euthyroid on combined therapy. For the frequency of side-effects, the thirteen cases mentioned above were included, giving a total of 118 cases. Eight cases showed an increase in goitre size and 15 cases had other side-effects, of which three were granulocytopenia due to propylthiouracil. The possibility of a higher frequency of mainly minor side-effects on combined therapy has to be balanced against the seemingly rapid and reliable therapeutic effect. Combined treatment, perhaps with even smaller doses than reported here, can be recommended in selected cases of thyrotoxicosis where a shortening of the thyrotoxic state seems of importance, or possibly where difficulties due to iodine exposure may be anticipated, provided adequate control measures are taken.

Sign in / Sign up

Export Citation Format

Share Document